Ligand-Based Virtual Screening (LBVS)
Fingerprint Similarity 
Pharmacophore Modeling 
QSAR Machine Learning When the target structure is unknown or undruggable by docking, LBVS extracts patterns from known actives to surface novel hits. We deploy similarity searching, pharmacophore modeling, and QSAR machine learning—each calibrated for speed and enrichment.
Why Ligand-Based Virtual Screening Is the Critical Bridge Between Actives and Novel Scaffolds?
No PDB entry. No AlphaFold confidence. No binding pocket. For seed-stage biotechs pioneering first-in-class targets, this is the reality. For pharma teams targeting membrane proteins or intrinsically disordered regions, crystallography may never deliver a structure. LBVS sidesteps this entirely by learning from known actives: similar structures, similar properties, similar binding. The challenge is not finding analogs—it is finding novel scaffolds that preserve activity without preserving substructure.
What Sets the Platform Apart
Fingerprint Similarity
Morgan, ECFP, and topological fingerprints encode molecular structure into searchable vectors. Tanimoto and Tversky coefficients rank candidates in milliseconds.
Pharmacophore Modeling
3D pharmacophore models extracted from known actives enforce essential features—hydrogen bonds, hydrophobic cores, aromatic rings—without requiring a receptor structure.
QSAR Machine Learning
SVM, Random Forest, and GNN models trained on active/inactive datasets predict bioactivity for novel scaffolds. ADMET Prediction & Modeling filters liabilities before synthesis.
The Ligand-Based Virtual Screening Suite
Similarity Searching
2D and 3D Fingerprint-Based Compound Retrieval
- Morgan & ECFP Fingerprints — Circular fingerprints encoding atom environments and connectivity patterns; robust to scaffold hopping.
- Shape & Pharmacophore Similarity — 3D shape overlay and pharmacophore feature matching for conformer-aware retrieval.
- Ideal For — Series expansion; analog discovery; Lead Optimization follow-up.
For virtual biotechs with one confirmed hit, similarity searching retrieves structurally related compounds from billion-compound libraries in hours. For pharma teams, data fusion—combining multiple fingerprints and similarity metrics—reduces false positives by requiring consensus across orthogonal descriptors.
Pharmacophore Searching
3D Feature-Based Virtual Screening
- Ligand-Based Pharmacophore Generation — Common feature extraction from 3–10+ known actives to identify shared binding elements.
- 3D-Pharmacophore Search — Database screening with feature sphere matching and tolerance optimization.
- Ideal For — Targets without crystal structures; scaffold-hopping campaigns; Hit Identification from diverse chemical space.
Pharmacophore searching transforms a set of actives into a 3D query. For biotechs facing patent cliffs, this identifies structurally novel compounds that match the essential feature set. When combined with Scaffold Hopping Analysis, pharmacophore constraints guide core replacement while preserving activity.
QSAR Modeling
Machine Learning Activity Prediction
- Descriptor Generation — Molecular weight, LogP, topological polar surface area, and hundreds of physicochemical descriptors.
- Model Training & Validation — SVM, Random Forest, Gradient Boosting, and GNN classifiers trained on curated active/inactive datasets with 5-fold cross-validation.
- Ideal For — Large-scale library pre-filtering; activity prediction for novel chemotypes; ADMET Prediction & Modeling integration.
QSAR models learn the boundary between active and inactive chemical space. For Ligand-Based Virtual Screening (LBVS) campaigns, this means predicting activity for millions of compounds without docking—enabling sublinear scaling with library size.
Platform Instrumentation
| Software / System | Core Capability |
|---|---|
| RDKit | Morgan, ECFP, topological torsion, and atom pair fingerprint generation; Tanimoto/Tversky similarity calculation. |
| MOE / ICM-Pro | 3D pharmacophore modeling, shape-based screening, and QSAR model development. |
| Schrödinger Phase + Canvas | 3D-QSAR pharmacophore generation and high-throughput fingerprint screening. |
| LigandScout | Automated pharmacophore feature detection and 3D database searching. |
| scikit-learn / XGBoost | SVM, Random Forest, and Gradient Boosting classifiers for QSAR model training. |
| PyTorch / DGL | Graph neural network (GNN) encoders for molecular graph embedding and similarity search. |
| NVIDIA A100 GPU Cluster | Parallelized fingerprint generation and GNN inference on billion-compound libraries. |
| PyMOL + Maestro | Pharmacophore visualization, hit inspection, and SAR analysis. |
Standardized Workflow
Project Workflow
A standardized, milestone-driven execution system. From known actives to ranked novel hits—managed by a single computational project team, tracked in real time.
01 Active Compound Review & Feature Extraction
- Known active collection: SMILES, SDF, biological activity data.
- Activity threshold definition (IC50, pIC50, Kd).
- Decoy or inactive compound collection for model validation.
Deliverable: Curated active/inactive dataset.
02 Method Selection & Model Training
- Method selection: similarity, pharmacophore, or QSAR.
- Fingerprint selection or pharmacophore feature extraction.
- QSAR model training and 5-fold cross-validation.
Deliverable: Trained model or pharmacophore hypothesis with validation metrics.
03 Virtual Screening Execution
- Database screening: public, commercial, or proprietary libraries.
- Similarity scoring, pharmacophore matching, or QSAR prediction.
- ADMET Prediction & Modeling filtering.
Deliverable: Ranked hit list with similarity or predicted activity scores.
04 Hit Refinement & Validation
- Hit clustering and scaffold diversity analysis.
- Binding Free Energy Calculation (FEP/TI, MM/PBSA) rescoring for top hits.
- Molecular Dynamics (MD) Simulations for pose stability (if contracted).
Deliverable: Refined hit dataset with stability metrics.
05 Report & Handoff
- Final LBVS report with ranked hit list.
- Structural rationale and synthetic accessibility.
- Direct handoff to Hit Biophysical Characterization or synthesis.
Deliverable: Final report + data package + transition plan to Hit to Lead or Lead Optimization.
Sample Requirements
| Requirement | Details |
|---|---|
| Known actives | 3–10+ confirmed actives in SMILES/SDF; include measured IC50, Kd, or pIC50 |
| Known inactives / decoys | Inactive compounds or property-matched decoys for QSAR model validation |
| Compound database | Public (ChEMBL, ZINC), commercial (Enamine), or proprietary; specify preferred vendor |
| Project scope | Hit identification, scaffold-hopping, or lead optimization |
| Prior data | Existing SAR, docking, or ADMET flags to guide method selection |
Standard Deliverables
- Curated active/inactive dataset with feature extraction documentation
- Fingerprint similarity ranking table or trained QSAR model with validation metrics
- Pharmacophore hypothesis with feature definitions and tolerance spheres (if applicable)
- Ranked hit list (top 100–500) with similarity scores or predicted activity probabilities
- Scaffold diversity analysis and synthetic accessibility assessment
- Electronic data package formatted for Structure-Based Virtual Screening (SBVS) or Hit to Lead handoff
Frequently Asked Questions
Case Study
Case Study: Fingerprint-Generating Networks Outperform Morgan Fingerprints in Virtual Screening
Published Evidence:
Monsia R, Bhattacharyya S. Efficient and Explainable Virtual Screening of Molecules through Fingerprint-Generating Networks Integrated with Artificial Neural Networks. ACS Omega. 2025 Jan 28;10(5):4896-4911.
Key Findings:
- GCN-ANN Architecture: Graph convolutional network generates task-specific molecular fingerprints integrated with artificial neural networks for virtual screening, outperforming standard Morgan fingerprints.
- Benchmark Performance: Tested across six protein systems (AChE, GST, PAP, PTP1B, NQO1, NQO2). ROC-AUC values ranged from 0.90–0.97, with recall improvements of 0.08–0.20 over Morgan fingerprint baselines.
- Efficiency Gains: Single-iteration screening achieved comparable precision to iterative docking protocols requiring 12+ iterations, reducing computational cost by an order of magnitude.
- Explainability: The model maps chemical space in relation to substructure recognition, providing interpretable binding affinity predictions.
Closing the Loop from Fingerprint to Hit:
For seed-stage biotechs with limited active compound data, this confirms that fingerprint-generating networks learn task-specific representations that generalize across targets—delivering higher recall without proportional data requirements. For pharma teams, the single-iteration efficiency means LBVS can replace multi-round docking triage, freeing HPC resources for Structure-Based Virtual Screening (SBVS) refinement. Our platform operationalizes this peer-reviewed architecture, pairing GCN fingerprint generation with Pharmacophore Modeling & Screening and ADMET Prediction & Modeling to deliver validated, developable hits.
Figure 1. Mean binding affinity (value of the data set for virtual hits compared to threshold scores for ligands across the six tested proteins). (Monsia R, et al. 2025)
Reference
- Monsia R, Bhattacharyya S. Efficient and Explainable Virtual Screening of Molecules through Fingerprint-Generating Networks Integrated with Artificial Neural Networks. ACS Omega. 2025 Jan 28;10(5):4896-4911.
Need ligand-based virtual screening to advance your hit identification pipeline? Our team can design an LBVS campaign tailored to your known actives, target class, and screening goals. Contact our scientific team today to start your project.
